Antigen Level Signals Response to Chemo for Pancreatic Cancer

This article originally appeared here.
Share this content:
Antigen Level Signals Response to Chemo for Pancreatic Cancer
Antigen Level Signals Response to Chemo for Pancreatic Cancer

MONDAY, Aug. 17, 2015 (HealthDay News) -- A drop in carbohydrate antigen (CA) 19-9 levels of more than 10 percent after two rounds of chemotherapy is associated with longer survival in patients with advanced pancreatic ductal adenocarcinoma (PDAC), according to a study published online Aug. 6 in the Journal of Gastroenterology and Hepatology.

Kwang Hyun Chung, from Seoul National University College of Medicine in South Korea, and colleagues assessed the correlation between early decrement in CA 19-9 concentration and prognosis of advanced PDAC (183 patients) after at least two rounds of chemotherapy (between January 2012 and December 2013). Serum CA 19-9 concentrations were measured at baseline and eight weeks after the initiation of chemotherapy.

The researchers found that overall survival (OS) and time to progression (TTP) were significantly longer for patients whose serum CA 19-9 concentration decreased more than 10 percent from baseline (103 patients) versus patients whose serum CA 19-9 did not decrease (80 patients; P < 0.001 for both OS and TTP). In both stage III and IV disease, CA19-9 decrement of more than 10 percent from baseline remained a significant factor for longer OS (hazard ratio for progression, 0.275; P < 0.001) and TTP (hazard ratio for progression, 0.322; P < 0.001), in multivariate analysis.

"The early decrement of CA 19-9 after the initiation of chemotherapy was an independent factor related [to] better survival outcomes in unresectable PDAC," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »